Is Lantern Pharma Inc. (LTRN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.8% / 30% | 79.5% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 0.8% / 33% | 79.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 1.0% / 33% | 93.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.8% / 33% | 79.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 1.0% / 33% | 93.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -104.6% | |
| Return on Assets (ROA) | -56.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$18M |
| Free Cash Flow | -$18M |
| Total Debt | $243,657 |
| Debt-to-Equity | 1.0 |
| Current Ratio | 3.3 |
| Total Assets | $26M |
Price & Trading
| Last Close | $2.09 |
| 50-Day MA | $2.75 |
| 200-Day MA | $3.57 |
| Avg Volume | 53K |
| Beta | 1.5 |
|
52-Week Range
$1.11
| |
About Lantern Pharma Inc. (LTRN)
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Lantern Pharma Inc. (LTRN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Lantern Pharma Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Lantern Pharma Inc.'s debt ratio?
Lantern Pharma Inc.'s debt ratio is 0.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Lantern Pharma Inc.'s key financial metrics?
Lantern Pharma Inc. has a market capitalization of $13M. Return on equity stands at -104.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.